July 2018
Volume 59, Issue 9
ARVO Annual Meeting Abstract  |   July 2018
Quantitative OCT-A analysis in patients treated with anti-VEGF therapy for macular edema.
Author Affiliations & Notes
  • Humberto Ruiz-Garcia
    Clinica Santa Lucia, Guadalajara, Jalisco, Mexico
    Universidad de Guadalajara, Guadalajara, Mexico
  • Mariana Ingolotti
    Universidad de Guadalajara, Guadalajara, Mexico
  • Perla Monserrat Madrigal-Ruiz
    Universidad de Guadalajara, Guadalajara, Mexico
  • Raul Lopez-Cervantes
    Universidad de Guadalajara, Guadalajara, Mexico
  • Enrique Roig-Melogranados
    Universidad de Guadalajara, Guadalajara, Mexico
    Clinica Santa Lucia, Guadalajara, Jalisco, Mexico
  • Footnotes
    Commercial Relationships   Humberto Ruiz-Garcia, None; Mariana Ingolotti, None; Perla Monserrat Madrigal-Ruiz, None; Raul Lopez-Cervantes, None; Enrique Roig-Melogranados, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2816. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Humberto Ruiz-Garcia, Mariana Ingolotti, Perla Monserrat Madrigal-Ruiz, Raul Lopez-Cervantes, Enrique Roig-Melogranados; Quantitative OCT-A analysis in patients treated with anti-VEGF therapy for macular edema.. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2816. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To describe and analyze optical coherence tomography angiography (OCT-A) quantitative changes pre and post anti-VEGF therapy in patients treated for macular edema.

Methods : Retrospective case series performed in a private practice setting in Mexico. Records of previously anti-VEGF (Bevacizumab, Ranibizumab) treated patients for macular edema due to diabetes or central/branch retinal vein occlusion who required additional injections were considered. Only OCT-A exams with signal strength above 7 were selected. Collected data included: demographics, measurements of Central Perfusion (CP) and Central Vessel (CV) using Cirrus Angioplex Metrix TM Software (Carl Zeiss Meditec, Dublin, CA), central macular thickness (CMT) using SD-OCT (Carl Zeiss Meditec, Dublin, CA), automated and manual foveal avascular zone assessment (FAZ).

Results : Thirty-two patients between March and September 2017 with complete data were included in this study. Average age was 63 ± 15 years. Average number of previously received injections was 6.13 ± 5.5. Mean CMT pre-treatment was 316±139 µm and CMT post-treatment was 267±82 µm (p=0.108). No significant changes in quantitative measurements were observed between pre (CP 0.15 ± 0.98 and CV 6.62 ± 4.30) and 1-month (CP 0.13 ± 0.10 and CV 6.03 ± 4.01) post-injected responder patients. Nevertheless, statistically significant positive correlation was found between central perfusion and central vessel measurements (R=0.944 p=0.001). Furthermore, central vessel measurements had a negative correlation with manually executed FAZ (R=-0.387 p= 0.029) and a positive correlation with SD-OCT central macular thickness (R= 0.404 p=0.022). Finally, mean pre and post injection signal strength (8.2±1.2; 8.03±1.5, respectively) correlated positively with both vessel (R= 0.471 p=0.007) and perfusion data (R=0.550 p=0.001).
Podes agregar promedio de espesor macular pre y post ?

Conclusions : There does not seem to be a significant change in central vessel and perfusion findings one month after anti-VEGF intravitreal injection in patients with macular edema. Data suggests that vessel and perfusion variables are strongly correlated.
Agregar alguna conclusion acerca de la herramienta ? poner lo que pensamos que pasa con la correlacion postiva con el OCT ?
Sugerimos que se deberia realizar el mismo trabajo en naive ??

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.